Cure8 news brief
Durable treatment responses matter to people with Crohn’s disease because sustained clinical remission and endoscopic improvement can mean fewer symptoms and less inflammation over time. Longer safety and durability data help patients and clinicians weigh treatment options after approval.
Adults with moderately to severely active Crohn’s disease, patients considering or already on Omvoh, gastroenterologists, and researchers following biologic treatments for IBD.
Lilly reported two-year results from the VIVID-2 open-label extension study of Omvoh in adults with moderately to severely active Crohn’s disease.
The company says most patients who were in clinical remission or had an endoscopic response at one year maintained those outcomes at two years; additional patients not in remission at year one achieved remission during year two. Safety findings were described as consistent with prior data.
The update comes after Omvoh’s FDA approval for Crohn’s disease in January 2025 (the drug was previously approved for ulcerative colitis). The study is ongoing as a long-term extension and Lilly noted plans for further regulatory submissions and pediatric/adult studies.
If you’re reading study updates as a patient, note this is an industry-reported summary of an open-label extension; it focuses on durability of response and safety over two years rather than randomized controlled comparisons.
This article is an industry/financial-news write-up summarizing company-reported results from an open-label extension (VIVID-2). Open-label extension data reflect outcomes on continuing treatment but do not replace randomized controlled trial evidence; details on study design, patient numbers, and independent peer review were not provided in this summary.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
These are multi‑year clinical results for a newly approved IL‑23p19 inhibitor (mirikizumab) showing sustained clinical and endoscopic benefit for many patients with moderate‑to‑severe Crohn’s disease, including some who...
The article spotlights duvakitug and the anti‑TL1A drug class as potential new options for ulcerative colitis and Crohn’s disease, especially for treatment‑experienced patients. Biomarker‑driven studies could help...
This announcement signals growing clinical and preclinical data for obefazimod, an investigational IBD drug; it includes a preclinical report on anti-fibrotic activity, a complication important in Crohn’s disease.
